NZ742447A - Non-human animals having a humanized lymphocyte-activation gene 3 - Google Patents

Non-human animals having a humanized lymphocyte-activation gene 3

Info

Publication number
NZ742447A
NZ742447A NZ742447A NZ74244716A NZ742447A NZ 742447 A NZ742447 A NZ 742447A NZ 742447 A NZ742447 A NZ 742447A NZ 74244716 A NZ74244716 A NZ 74244716A NZ 742447 A NZ742447 A NZ 742447A
Authority
NZ
New Zealand
Prior art keywords
lag
rodent
humanized
polypeptide
gene
Prior art date
Application number
NZ742447A
Other languages
English (en)
Inventor
Andrew J Murphy
Elena Burova
Alexander O Mujica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ742447A publication Critical patent/NZ742447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
NZ742447A 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3 NZ742447A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258181P 2015-11-20 2015-11-20
US201662370430P 2016-08-03 2016-08-03
PCT/US2016/062733 WO2017087780A1 (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Publications (1)

Publication Number Publication Date
NZ742447A true NZ742447A (en) 2022-12-23

Family

ID=57543170

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ742447A NZ742447A (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Country Status (26)

Country Link
US (4) US10306874B2 (enExample)
EP (1) EP3376857B1 (enExample)
JP (1) JP6997708B2 (enExample)
KR (1) KR102454546B1 (enExample)
CN (1) CN108366548B (enExample)
AU (1) AU2016358101B2 (enExample)
BR (1) BR112018010158A2 (enExample)
CA (1) CA3003786C (enExample)
CY (1) CY1124171T1 (enExample)
DK (1) DK3376857T3 (enExample)
ES (1) ES2872799T3 (enExample)
HR (1) HRP20210824T1 (enExample)
HU (1) HUE054612T2 (enExample)
IL (1) IL258841B (enExample)
LT (1) LT3376857T (enExample)
MX (1) MX2018005389A (enExample)
NZ (1) NZ742447A (enExample)
PL (1) PL3376857T3 (enExample)
PT (1) PT3376857T (enExample)
RS (1) RS61866B1 (enExample)
RU (1) RU2745403C2 (enExample)
SG (1) SG11201803409UA (enExample)
SI (1) SI3376857T1 (enExample)
SM (1) SMT202100299T1 (enExample)
WO (1) WO2017087780A1 (enExample)
ZA (1) ZA201802717B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808775B1 (en) 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
EP3895529B1 (en) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
EP3476865B1 (en) 2016-06-28 2023-09-13 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Method for constructing pd-1 gene-modified humanized animal model and use thereof
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN108070613B (zh) 2016-11-11 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018086583A1 (en) * 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric lag-3
EP4484562A3 (en) * 2017-06-27 2025-03-26 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized asgr1 locus
CA3068072A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
CN110891420B (zh) 2017-07-31 2022-06-03 瑞泽恩制药公司 Cas转基因小鼠胚胎干细胞和小鼠及其应用
JP7139419B2 (ja) 2017-09-29 2022-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
IL274740B2 (en) * 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
KR20240038811A (ko) 2018-03-19 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
WO2020125763A1 (en) * 2018-12-20 2020-06-25 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric lag3
CN109929875B (zh) * 2019-03-12 2021-02-19 江苏集萃药康生物科技股份有限公司 一种lag3基因人源化动物模型的构建方法及其应用
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CA3137764A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
CA3167557A1 (en) * 2020-04-21 2021-10-28 Davor Frleta Non-human animals having a humanized cxcl13 gene
US12582104B2 (en) 2021-12-08 2026-03-24 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2025163140A1 (en) * 2024-02-02 2025-08-07 Vacara Ab Physiologic humanized mice for studies of mhc class ii function

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
HUE053444T2 (hu) * 2011-10-28 2021-06-28 Regeneron Pharma Genetikailag módosított T-sejt receptoros egerek
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
IN2015DN02032A (enExample) 2012-09-07 2015-08-14 Univ Yale
WO2014043708A1 (en) * 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
ES2884598T3 (es) 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
MX368931B (es) 2013-09-23 2019-10-22 Regeneron Pharma Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
NO2785538T3 (enExample) 2014-05-07 2018-08-04
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
KR102659123B1 (ko) 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
FI3850946T3 (fi) 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni
EP3808775B1 (en) 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물

Also Published As

Publication number Publication date
US12096754B2 (en) 2024-09-24
US11102961B2 (en) 2021-08-31
CN108366548A (zh) 2018-08-03
EP3376857B1 (en) 2021-02-24
AU2016358101B2 (en) 2022-12-01
RU2745403C2 (ru) 2021-03-24
WO2017087780A1 (en) 2017-05-26
JP6997708B2 (ja) 2022-02-04
US20240397919A1 (en) 2024-12-05
EP3376857A1 (en) 2018-09-26
MX2018005389A (es) 2018-09-05
DK3376857T3 (da) 2021-05-25
US10306874B2 (en) 2019-06-04
RU2018117944A3 (enExample) 2020-04-06
JP2018533963A (ja) 2018-11-22
HUE054612T2 (hu) 2021-09-28
CA3003786A1 (en) 2017-05-26
KR20180083381A (ko) 2018-07-20
BR112018010158A2 (pt) 2018-11-21
SMT202100299T1 (it) 2021-07-12
CY1124171T1 (el) 2022-05-27
CN108366548B (zh) 2021-10-08
ES2872799T3 (es) 2021-11-02
IL258841B (en) 2021-04-29
US20210360908A1 (en) 2021-11-25
CA3003786C (en) 2023-09-12
AU2016358101A1 (en) 2018-05-31
IL258841A (en) 2018-06-28
RS61866B1 (sr) 2021-06-30
US20190320632A1 (en) 2019-10-24
PL3376857T3 (pl) 2021-09-13
HK1253683A1 (en) 2019-06-28
LT3376857T (lt) 2021-06-25
RU2018117944A (ru) 2019-12-20
US20170142943A1 (en) 2017-05-25
ZA201802717B (en) 2023-05-31
SI3376857T1 (sl) 2021-09-30
SG11201803409UA (en) 2018-05-30
KR102454546B1 (ko) 2022-10-14
PT3376857T (pt) 2021-05-27
HRP20210824T1 (hr) 2021-07-09

Similar Documents

Publication Publication Date Title
Lommel et al. Protein O-mannosylation is crucial for E-cadherin–mediated cell adhesion
AU2023233125B2 (en) Anti-KRAS-G12D T cell receptors
US12077592B2 (en) GPRC5D chimeric antigen receptors and cells expressing the same
Hutchings et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Kleinau et al. Structural–functional features of the thyrotropin receptor: a class A G-protein-coupled receptor at work
HRP20210824T1 (hr) Neljudske životinje koje imaju humanizirani gen 3 za aktiviranje limfocita
Zhao et al. Female-to-male sex reversal in mice caused by transgenic overexpression of Dmrt1
AU2023200608A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
Li et al. Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition
Moody et al. Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding
Pasch et al. The LINC complex component Sun4 plays a crucial role in sperm head formation and fertility
Rossi et al. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation
ES2913415T3 (es) Anticuerpo humanizado contra gangliósido GD2 o-acetilado (OAcGD2)
JP2017513478A5 (enExample)
Lindenmaier et al. Dystroglycan is a scaffold for extracellular axon guidance decisions
FI3808775T3 (fi) Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusteri 274 -geeni
JP2018533963A5 (enExample)
CN112955179A (zh) 拮抗性抗肿瘤坏死因子受体超家族多肽
CN105612175A (zh) 基于IL-15和IL-15Rαsushi结构域的调节因子
JP2019530431A5 (enExample)
Ellis et al. The talin head domain reinforces integrin-mediated adhesion by promoting adhesion complex stability and clustering
Zhang et al. Haploinsufficiency for the murine orthologue of Chlamydomonas PF20 disrupts spermatogenesis
Meier et al. Genetic control of courtship behavior in the housefly: evidence for a conserved bifurcation of the sex-determining pathway
Tu et al. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells
Ueda et al. Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3–mediated therapeutics

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

LAPS Patent lapsed